HK1094530A1 - N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt - Google Patents

N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Info

Publication number
HK1094530A1
HK1094530A1 HK07101468.4A HK07101468A HK1094530A1 HK 1094530 A1 HK1094530 A1 HK 1094530A1 HK 07101468 A HK07101468 A HK 07101468A HK 1094530 A1 HK1094530 A1 HK 1094530A1
Authority
HK
Hong Kong
Prior art keywords
benzamidine
pentoxy
thiazol
phenoxy
isopropyl
Prior art date
Application number
HK07101468.4A
Other languages
English (en)
Inventor
Jei Man Ryu
Jin Soo Lee
Dong Hyuk Shin
Seung Kyoo Seong
Soon Ki Cho
Chan Seok Jeon
Young Goo Jin
Ki Young Lee
Se Hyun Jung
Eun Hee Cho
Seok Hoon Ahn
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36498212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1094530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Publication of HK1094530A1 publication Critical patent/HK1094530A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HK07101468.4A 2004-11-23 2007-02-08 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt HK1094530A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040096390 2004-11-23
PCT/KR2005/003934 WO2006057501A1 (en) 2004-11-23 2005-11-22 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Publications (1)

Publication Number Publication Date
HK1094530A1 true HK1094530A1 (en) 2007-04-04

Family

ID=36498212

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101468.4A HK1094530A1 (en) 2004-11-23 2007-02-08 N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt

Country Status (19)

Country Link
US (2) US20090176846A1 (de)
EP (2) EP1814593A4 (de)
JP (2) JP4774053B2 (de)
KR (2) KR101047042B1 (de)
CN (3) CN101693029B (de)
AT (1) ATE445397T1 (de)
AU (2) AU2005307994B2 (de)
BR (2) BRPI0514386B8 (de)
CA (2) CA2552766C (de)
DE (1) DE602005017118D1 (de)
DK (1) DK1701722T3 (de)
ES (1) ES2333739T3 (de)
HK (1) HK1094530A1 (de)
IL (2) IL180985A (de)
NZ (1) NZ555725A (de)
PT (1) PT1701722E (de)
RU (1) RU2361867C2 (de)
WO (2) WO2006057507A1 (de)
ZA (2) ZA200700485B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997367B (zh) * 2004-07-05 2010-11-24 同和药品株式会社 预防和治疗过敏性炎症的组合物
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
CA2552766C (en) * 2004-11-23 2010-08-17 Dong Wha Pharmaceutical Ind. Co., Ltd. N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine bis(methanesulfonate)
CN101652355B (zh) * 2007-04-19 2012-11-07 同和药品株式会社 N-羟基-4-{5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苄脒2乙磺酸盐、其制备方法和包含其的药物组合物
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
EP3444363B1 (de) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
MX339685B (es) † 2011-07-28 2016-06-06 Rigel Pharmaceuticals Inc Formulaciones de (trimetoxifenilamino) pirimidinilo nuevas.
JP6292744B2 (ja) * 2012-09-19 2018-03-14 富士カプセル株式会社 医薬品組成物
WO2014119767A1 (ja) * 2013-01-31 2014-08-07 沢井製薬株式会社 テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
TW201713343A (zh) 2015-04-28 2017-04-16 安斯泰來製藥股份有限公司 經口投與用醫藥組成物
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS
JP7374885B2 (ja) * 2017-08-18 2023-11-07 アッヴィ・インコーポレイテッド 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤
KR102276547B1 (ko) * 2020-09-04 2021-07-13 주식회사유한양행 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
EP0379579A4 (en) * 1988-02-03 1991-01-02 Yoshitomi Pharmaceutical Industries, Ltd. Pharmaceutical composition having improved releasability
US5914329A (en) * 1996-11-26 1999-06-22 Pfizer Inc. Dimesylate salts of neuropeptide Y ligands
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
PL354619A1 (en) * 1999-10-28 2004-02-09 Sankyo Company, Limited Benzamidine derivatives
KR100454767B1 (ko) * 2001-07-19 2004-11-03 동화약품공업주식회사 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
ES2448501T3 (es) * 2002-03-06 2014-03-14 Effrx Pharmaceuticals Sa Composiciones efervescentes que comprenden bisfosfonatos
JP2005532291A (ja) * 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
KR101173580B1 (ko) * 2003-03-18 2012-08-13 코와 가부시키가이샤 제산제 조성물
CA2552766C (en) * 2004-11-23 2010-08-17 Dong Wha Pharmaceutical Ind. Co., Ltd. N-hydroxy-4- {5- [4- (5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine bis(methanesulfonate)

Also Published As

Publication number Publication date
ZA200704236B (en) 2008-11-26
BRPI0514386A (pt) 2008-06-10
IL182647A (en) 2011-04-28
CA2585003A1 (en) 2006-06-01
US20070254930A1 (en) 2007-11-01
ES2333739T3 (es) 2010-02-26
AU2005300239B2 (en) 2009-08-06
US20090176846A1 (en) 2009-07-09
EP1701722A1 (de) 2006-09-20
EP1701722A4 (de) 2007-05-16
AU2005307994B2 (en) 2009-07-23
AU2005307994A1 (en) 2006-06-01
CN100574756C (zh) 2009-12-30
KR20060057514A (ko) 2006-05-26
KR20060057511A (ko) 2006-05-26
KR100716389B1 (ko) 2007-05-11
CA2585003C (en) 2010-08-17
EP1814593A4 (de) 2012-09-05
JP4773456B2 (ja) 2011-09-14
BRPI0517396A (pt) 2008-10-14
JP2008508264A (ja) 2008-03-21
IL180985A (en) 2012-02-29
RU2361867C2 (ru) 2009-07-20
CN101056658A (zh) 2007-10-17
NZ555725A (en) 2008-07-31
IL182647A0 (en) 2007-07-24
CN1905871A (zh) 2007-01-31
KR101047042B1 (ko) 2011-07-06
CN101693029B (zh) 2011-11-02
DE602005017118D1 (de) 2009-11-26
CA2552766A1 (en) 2006-06-01
CN101693029A (zh) 2010-04-14
WO2006057507A1 (en) 2006-06-01
CN1905871B (zh) 2010-07-07
EP1701722B1 (de) 2009-10-14
RU2007123614A (ru) 2008-12-27
JP2008520655A (ja) 2008-06-19
JP4774053B2 (ja) 2011-09-14
BRPI0514386B8 (pt) 2021-05-25
EP1814593A1 (de) 2007-08-08
ATE445397T1 (de) 2009-10-15
IL180985A0 (en) 2007-07-04
CA2552766C (en) 2010-08-17
PT1701722E (pt) 2009-12-10
DK1701722T3 (da) 2010-01-11
WO2006057501A1 (en) 2006-06-01
ZA200700485B (en) 2007-11-28
BRPI0514386B1 (pt) 2021-02-09
AU2005300239A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
HK1094530A1 (en) N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt
WO2003097622A3 (en) Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof
CY1107238T1 (el) Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
UA92354C2 (en) Amino acid salts of rosiglitazone
WO2008126899A1 (ja) ５員環へテロ環誘導体及びその医薬用途
WO2006003471A3 (en) Process for the preparation of pramipexole by chiral chromatography
WO2007009656A3 (de) Neues 1,4-benzothiazepin-1,1-dioxidderivat mit verbesserten eigenschaften, verfahren zu dessen herstellung, diese verbindung enthaltende arzneimittel und dessen verwendung
WO2006067456A3 (en) Process for preparing rosuvastatin
WO2005105749A3 (en) Process for making montelukast and intermediates therefor
EP1541570A4 (de) Neue physiologisch wirksame substanz
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
WO2011141933A3 (en) Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts
WO2007057225A3 (en) Process for making montelukast and intermediates therefor
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
WO2008133128A1 (ja) 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途
BRPI0607085A2 (pt) derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes
GB0410013D0 (en) Process
WO2009012201A3 (en) Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides
WO2005012273A3 (en) Process for the preparation of substituted thiazoles
WO2009069311A1 (ja) ３－メルカプトアニリン化合物の製造法
WO2005021542A3 (en) Process for the preparation of pioglitazone
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique